PF-Atlas › Clinical Trials › NCT04730895
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.
Oral 13 cis retinoic acid · Phase 1
Registry ID
NCT04730895
Phase
Phase 1
Status
Unknown
Drug / intervention
Oral 13 cis retinoic acid
Sponsor
Kafrelsheikh University
Start
2021-07
About this trial
Oral 13 cis retinoic acid is evaluated in NCT04730895, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Kafrelsheikh University. Current status: Unknown.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04730895 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.